研究单位：[1]Klus Pharma Inc.[2]Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.[3]Beijing Cancer Hospital,Beijing,Beijing,China,100142[4]Fujian Cancer Hospital,Fuzhou,Fujian,China,350014[5]Sun Yat-sen University, Cancer Center,Guangzhou,Guangdong,China,510060[6]Harbin Medical University Cancer Hospital,Harbin,Heilongjiang,China,150081[7]The First Affiliated Hospital of Zhengzhou University,Zhengzhou,Henan,China,450018[8]Hunan Cancer Hospital,Changsha,Hunan,China,410013[9]The First Affiliated Hospital of Nanchang University,Nanchang,Jiangxi,China,330006[10]Jilin Cancer Hospital,Changchun,Jilin,China,130021[11]The First Hospital of Chinese Medical University,Shenyang,Liaoning,China,110002[12]Shanghai Chest Hospital,Shanghai,Shanghai,China,200030[13]Shanghai East Hospital,Shanghai,Shanghai,China,200123[14]West China Hospital Si Chuan University,Chengdu,Sichuan,China,610041[15]Sichuan Cancer Hospital,Chengdu,Sichuan,China,610042[16]The First Affiliated Hospital, Zhejiang University School of Medicine,Hangzhou,Zhejiang,China,310003
研究目的：
The purpose of this study is to evaluate the safety, tolerability and objective response rate of SKB264 as combination with therapy in subjects with advanced or metastatic non-small cell lung cancer.
